Biotechnology

Frequency tech firm Hapbee adds a marketing maestro to its board, aiming to rebrand from niche gadget to a mainstream player in the booming wellness economy.

A strategic investment from Krieger Capital will fuel Global Key Solutions' AI platform, which transforms complex regulatory data into actionable safety insights.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

The acquisition strengthens the independent distributor's hold on the booming plasma therapy market, promising wider access to critical, complex medications.

The strategic acquisition unites AI design with sequencing analytics, creating an end-to-end platform poised to accelerate RNA therapeutic development.

Avant Technologies is evaluating a therapy to protect insulin cells from immune attack, a breakthrough that could end the need for harsh drugs.

A new COVID-19 drug targets patients who can't take Paxlovid, while a once-a-month pill could revolutionize how we prevent seasonal influenza.

With new VP of Sales David Florez, Peer AI aims to accelerate its mission of transforming regulatory documentation as the pharma industry moves beyond AI pilots.

Leios Therapeutics partners with BNC Korea, securing a key investment and pathway to Asia's lucrative body contouring market for its 10XB-101 injectable.

With fresh funding, Primmune is advancing its unique TLR7 agonist, designed for efficacy without severe side effects, into a pivotal melanoma trial in Australia.

A first-in-class oral therapy targeting cellular metabolism has entered patient trials, offering new hope for a disease-modifying treatment for eczema.

Janux Therapeutics appoints Dr. William Go, a key leader behind YESCARTA®'s approval, as CMO to steer its novel immunotherapy pipeline through critical trials.

A new partnership between Mair Therapeutics and Radboud University aims to fix the cell's waste disposal system, a novel approach for Parkinson's disease.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.

A new partnership aims to accelerate a pipeline of innovative multi-functional fusion proteins, potentially reshaping treatment for cancer and autoimmune disease.

Flexible Solutions posts modest 2025 revenue gains, but a major strategic shift to food-grade products and new factories sets the stage for a breakout year.

Researchers discover a potent, natural moisturizer from Indonesian seaweed, promising a sustainable and safer alternative to synthetic skincare ingredients.

A new Canadian patent for a metformin-based eye drop could revolutionize treatment for degenerative eye diseases in both humans and their canine companions.

Insilico Medicine's AI-powered drug ISM8969, a brain-penetrant inhibitor, has been cleared by the FDA for clinical trials in Parkinson's disease.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.